Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.
Gurbakhash Kaur, MD, an assistant professor in the Department of Internal Medicine at University of Texas Southwestern Medical Center, discusses the use of bispecific T-cell engagers (BiTEs) as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.
According to Kaur, BiTEs provide an off-the-shelf approach for patients. CAR T cells require lymphodepletion, after which the cells need to be engineered. For patients in crisis, they may not be able to wait for CAR T cells to be manufactured. According to Kaur, both CAR T cells and BiTE therapies will have a major role in the treatment of multiple myeloma.
0:08 | BiTEs, especially with AMG 420, are also BCMA-targeted agents, but that will be an off-the-shelf type of approach, whereas with CAR T cells you need to give lymphodepletion and wait a couple of weeks for the cells to be engineered. Many patients, when they are in crisis and they run out of options, don’t have the time to wait for a CAR T-cell to be manufactured. Both of these therapies, CAR T cells and BiTE therapies, will have a major role to play in multiple myeloma treatment.
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More
Enhancing Outcomes in Myeloma With CAR T Cells and Bispecific Antibodies
March 18th 2024March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.
Read More
FDA’s ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma
March 15th 2024During an Oncologic Drug Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide.
Read More